Tradegate
11.06.26 | 21:50
0,242 Euro
-1,63 % -0,004
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,242 | 0,250 | 07:40 | |
| 0,242 | 0,250 | 07:30 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | IGC Pharma, Inc.: IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis | 390 | ACCESS Newswire | Company Continuing Limited Over-Enrollment Activities to Account for Attrition and Support Robust Modified Intent-to-Treat, End-of-Treatment and Exploratory Analyses POTOMAC, MD / ACCESS Newswire /... ► Artikel lesen | |
| IGC PHARMA Aktie jetzt für 0€ handeln | |||||
| Di | IGC Pharma, Inc.: Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts | 285 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / June 9, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease,... ► Artikel lesen | |
| Mo | IGC Pharma, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 02.06. | IGC Pharma, Inc.: IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis | 305 | ACCESS Newswire | Approximately 80% of target participants have completed trial participation, strengthening momentum toward database lock and topline analysis POTOMAC, MD / ACCESS Newswire / June 2, 2026 / IGC Pharma... ► Artikel lesen | |
| 19.05. | IGC Pharma, Inc.: IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment | 548 | ACCESS Newswire | - Continued Advancement of CALMA Phase 2 Trial - POTOMAC, MD / ACCESS Newswire / May 19, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company... ► Artikel lesen | |
| 19.05. | IGC Pharma GAAP EPS of -$0.02 in-line, revenue of $0.32M beats by $0.09M | 3 | Seeking Alpha | ||
| 15.05. | IGC Pharma, Inc.: IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference | 335 | ACCESS Newswire | Research highlights advanced imaging analytics that may support Alzheimer's disease monitoring, patient stratification, and future therapeutic development. POTOMAC, MD / ACCESS Newswire / May 15, 2026... ► Artikel lesen | |
| 28.04. | IGC Pharma, Inc.: IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase | 463 | ACCESS Newswire | Outreach initiative supports awareness of agitation and patient engagement as enrollment approaches completion POTOMAC, MD / ACCESS Newswire / April 28, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC"... ► Artikel lesen | |
| 22.04. | IGC Pharma, Inc.: IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion | 386 | ACCESS Newswire | Behavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation study POTOMAC, MD / ACCESS Newswire / April 22, 2026 / IGC Pharma, Inc. (NYSE American:IGC)... ► Artikel lesen | |
| 20.04. | IGC Pharma, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 20.04. | IGC Pharma, Inc.: IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia | 351 | ACCESS Newswire | Authorization provides regulated capability to evaluate emerging therapeutic approaches alongside Phase 2 CALMA trial approaching completion POTOMAC, MD / ACCESS Newswire / April 20, 2026 / IGC Pharma... ► Artikel lesen | |
| 14.04. | IGC Pharma, Inc.: IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout | 389 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / April 14, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that it has approximately 80% patient enrollment in its Phase 2 CALMA clinical... ► Artikel lesen | |
| 11.04. | New to The Street Broadcasts on Bloomberg Television at 6:30 PM EST Featuring IGC Pharma, Vivos Therapeutics, Acurx Pharmaceuticals, and Equinox Gold | 1.215 | ACCESS Newswire | Special continuing M&A Segment with Senior M&A Partner at Sullivan & Cromwell LLP, Frank Aquila NEW YORK CITY, NY / ACCESS Newswire / April 11, 2026 / New to The Street announces its latest nationally... ► Artikel lesen | |
| 08.04. | IGC Pharma, Inc.: Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts | 435 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / April 8, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company with its lead program currently in a Phase 2 CALMA... ► Artikel lesen | |
| 07.04. | IGC Pharma, Inc.: IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease | 300 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / April 7, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing innovative treatments for Alzheimer's... ► Artikel lesen | |
| 30.03. | IGC Pharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.03. | IGC Pharma, Inc.: IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness | 298 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / March 30, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease... ► Artikel lesen | |
| 25.03. | New to The Street and IGC Pharma Launch Strategic 12-Part National Media Partnership to Accelerate Investor Awareness and Market Positioning | 289 | ACCESS Newswire | NEW YORK, NY / ACCESS Newswire / March 25, 2026 / New to The Street, a premier financial media platform known for its national television distribution and integrated investor engagement strategy, today... ► Artikel lesen | |
| 19.03. | IGC Pharma reports results | 7 | Seeking Alpha | ||
| 19.03. | IGC Pharma, Inc.: IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025 | 549 | ACCESS Newswire | - Strategic Pivot to Pure-Play Biotech - POTOMAC, MD / ACCESS Newswire / March 19, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing... ► Artikel lesen |
1 2 3 4 Weiter >>
66 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 35,790 | 0,00 % | Kampf dem Welthunger und Kampf um den Milliardenmarkt Agrartech! Neue Impulse und aktuelle News bei Bayer, Nutrien und MustGrow Biologics | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Der globale Hunger nimmt seit Jahren dramatisch zu und betrifft heute schon über 750 Millionen Menschen weltweit. Geopolitische Konflikte... ► Artikel lesen | |
| NOVO NORDISK | 37,620 | 0,00 % | Novo Nordisk: Zulassung für Millionen zum Greifen nah | Der dänische Biopharma-Riese hat in dieser Woche in den Vereinigten Arabischen Emiraten (VAE) seine Wegovy-Pille lanciert. Es handelt sich damit um den ersten Markt außerhalb der USA, den Novo Nordisk... ► Artikel lesen | |
| PFIZER | 22,675 | +0,31 % | Community Rückblick: wO User zu Todesfall bei Newron Studie: "...der Rekrutierungsstop ist Formsache" | © Foto: Newron Pharmaceuticals SpAFDA-Stopp, ein Todesfall im klinischen Studienprogramm und große Hoffnungen auf den Schizophrenie-Wirkstoff Evenamide: Newron sorgt wieder für Debatten. Zwischen Zuversicht... ► Artikel lesen | |
| NOVARTIS | 132,70 | +0,18 % | Zelltherapien rücken in den Mittelpunkt: Warum Mesoblast von einem grundlegenden Wandel in der Biotechnologie profitieren könnte | ||
| MERCK KGAA | 135,40 | 0,00 % | EQS-PVR: Merck KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Merck KGaA
Merck KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
08.06.2026 / 16:57 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| GILEAD SCIENCES | 108,70 | +0,04 % | Can Gilead Sciences HIV Franchise Drive Long-Term Growth? | ||
| AURORA CANNABIS | 2,628 | -1,05 % | Aurora Cannabis Inc.: Aurora Cannabis Announces Full Year and Fiscal 2026 Fourth Quarter Results with Record Annual Revenue and Adjusted EBITDA | NASDAQ | TSX: ACB
Achieves Record Annual Global Medical Cannabis Net Revenue1 of $288.6 million, representing 18% YoY growth
Delivers Record Annual Adjusted EBITDA1 of $53.8 million... ► Artikel lesen | |
| SANOFI | 76,37 | -0,03 % | DEUTSCHE BANK RESEARCH stuft SANOFI auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Sanofi mit einem Kursziel von 100 Euro auf "Buy" belassen. Dies schrieb Emmanuel Papadakis in seinem am Dienstag vorliegenden... ► Artikel lesen | |
| ABBVIE | 197,00 | +1,47 % | Will Skyrizi & Rinvoq Continue to Drive AbbVie's Topline Through 2026? | ||
| CANOPY GROWTH | 0,868 | -0,96 % | Canopy Growth Corporation: Canopy Growth Relaunches Tweed Brand in Germany with New MTL Cannabis Strain Lineup, Marking First International Release following Acquisition | Pablo's Revenge, Dante'z Inferno, and Frost'd Flakes launched under Tweed brand Up to five additional strains expected to follow in June 2026 Company targeting rapid growth in Germany's medical... ► Artikel lesen | |
| ELI LILLY | 1.000,80 | -0,16 % | PRESSESPIEGEL/Unternehmen: LUFTHANSA, ELI LILLY, BOEHRINGER INGELHEIM, TGI, EON | DJ PRESSESPIEGEL/Unternehmen
Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires.
LUFTHANSA - Die Airline musste einen Flug mit einer Boeing 787 an die... ► Artikel lesen | |
| MERCK & CO | 104,80 | +0,50 % | LifeSpan Vision Ventures: Lifespan Portfolio Company Rejuvenate Bio Closes $6 Million Financing and R&D Collaboration with Merck Animal Health | Milestone financing and R&D collaboration advances gene therapy programs targeting chronic and age-related diseases in companion animals. NORWALK, Conn., June 11, 2026 /PRNewswire/ -- Lifespan... ► Artikel lesen | |
| ASTRAZENECA | 158,05 | +0,35 % | Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know | ||
| TILRAY BRANDS | 4,405 | -0,56 % | Tilray Brands, Inc.: Tilray Medical Deutschland bringt ARX auf den Markt, eine neue Premium-Marke für medizinisches Cannabis aus deutschem Anbau | Die neue Marke vereint bewährte Genetik, deutsches Anbauknow-how und strenge Qualitätsstandards, um Patienten und medizinisches Fachpersonal in ganz Deutschland zu unterstützenNEUMÜNSTER, Deutschland... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 49,180 | +0,08 % | Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue. |
IGC PHARMA INC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von -0,004 (-1,63 %) liegt der Kurs bei 0,242 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IGC PHARMA INC finden Sie auf Wallstreet Online.